Nothing Special   »   [go: up one dir, main page]

NZ718163A - Extended-release formulation for reducing the frequency of urination and method of use thereof - Google Patents

Extended-release formulation for reducing the frequency of urination and method of use thereof

Info

Publication number
NZ718163A
NZ718163A NZ718163A NZ71816313A NZ718163A NZ 718163 A NZ718163 A NZ 718163A NZ 718163 A NZ718163 A NZ 718163A NZ 71816313 A NZ71816313 A NZ 71816313A NZ 718163 A NZ718163 A NZ 718163A
Authority
NZ
New Zealand
Prior art keywords
urination
extended
frequency
reducing
release formulation
Prior art date
Application number
NZ718163A
Inventor
David A Dill
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Publication of NZ718163A publication Critical patent/NZ718163A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising zolpidem and one or moren analgesic agents formulated in for oral administration. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release.
NZ718163A 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof NZ718163A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ630471A NZ630471A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof

Publications (1)

Publication Number Publication Date
NZ718163A true NZ718163A (en) 2017-09-29

Family

ID=49223209

Family Applications (6)

Application Number Title Priority Date Filing Date
NZ712594A NZ712594A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ718163A NZ718163A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ714288A NZ714288A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ630471A NZ630471A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ714662A NZ714662A (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ628079A NZ628079A (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ712594A NZ712594A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof

Family Applications After (4)

Application Number Title Priority Date Filing Date
NZ714288A NZ714288A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ630471A NZ630471A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ714662A NZ714662A (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ628079A NZ628079A (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof

Country Status (15)

Country Link
EP (2) EP2827852A4 (en)
JP (5) JP2015510928A (en)
KR (4) KR20140134333A (en)
CN (4) CN107157991A (en)
AU (4) AU2013235518B2 (en)
BR (2) BR112014020271A8 (en)
CA (2) CA2866853A1 (en)
HK (3) HK1251469A1 (en)
MX (3) MX2014011128A (en)
MY (2) MY174090A (en)
NZ (6) NZ712594A (en)
RU (3) RU2669565C2 (en)
SG (2) SG11201500408VA (en)
WO (2) WO2013142197A1 (en)
ZA (2) ZA201405862B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
ES2910361T3 (en) 2013-07-23 2022-05-12 Serenity Pharmaceuticals Llc Compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
CN106714805A (en) * 2014-06-06 2017-05-24 韦尔斯利医药有限公司 Pharmaceutical formulation for reducing frequency of urination and method of use thereof
KR101809908B1 (en) * 2014-07-21 2018-01-25 주식회사 종근당 Pharmaceutical composition comprising 5-α reductase inhibitor
JP2017535567A (en) * 2014-11-20 2017-11-30 アラーガン、インコーポレイテッドAllergan,Incorporated Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
CN108430465A (en) * 2015-09-30 2018-08-21 韦尔斯利医药有限公司 Composition, its manufacturing method and purposes for alleviating frequent micturition
EP3355864A4 (en) * 2015-09-30 2019-05-22 Wellesley Pharmaceuticals, LLC Composition for reducing the frequency of urination, method of making and use thereof
CN105238124B (en) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 A kind of antibacterial mastic powder
JP6294924B2 (en) 2016-09-05 2018-03-14 株式会社Subaru Vehicle travel control device

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1296417A (en) * 1998-02-10 2001-05-23 卫福有限公司 Controlled release formulations
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
DE10116978A1 (en) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa opiate agonists for the treatment of diseases of the bladder
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005526040A (en) * 2002-02-19 2005-09-02 ファルマシア・コーポレーション Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
CN100355419C (en) * 2002-06-07 2007-12-19 安斯泰来制药有限公司 Therapeutic agent for overactive bladder
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
US20040198822A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmacueticals, Inc. Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
EP1605929B1 (en) * 2003-03-21 2014-04-23 McNeil-PPC, Inc. Non-steroidal anti-inflammatory drug dosing regimen
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
EP2400300A1 (en) * 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
TW200716140A (en) * 2005-06-17 2007-05-01 Dynamis Therapeutics Inc Treatment of inflammatory conditions
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
PL1933833T3 (en) * 2005-09-02 2011-09-30 Theravida Inc Therapy for the treatment of overactive bladder
US20120064159A1 (en) * 2009-05-28 2012-03-15 Aptapharma, Inc. Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Also Published As

Publication number Publication date
JP2016172752A (en) 2016-09-29
CA2866853A1 (en) 2013-07-26
AU2013235507A1 (en) 2014-08-21
JP2018024693A (en) 2018-02-15
MY174090A (en) 2020-03-09
WO2013142197A1 (en) 2013-09-26
ZA201406146B (en) 2016-08-31
AU2013235518B2 (en) 2017-03-02
AU2017203139A1 (en) 2017-06-01
HK1251469A1 (en) 2019-02-01
RU2014142025A (en) 2016-05-10
AU2017203246A1 (en) 2017-06-08
EP2827852A1 (en) 2015-01-28
KR20170015537A (en) 2017-02-08
MX2014011128A (en) 2015-08-10
KR20190003840A (en) 2019-01-09
BR112014020271A8 (en) 2017-07-11
CN104302284A (en) 2015-01-21
KR20140134333A (en) 2014-11-21
RU2016133305A3 (en) 2018-12-10
SG11201500408VA (en) 2015-03-30
AU2017203139B2 (en) 2018-07-19
EP2827851A1 (en) 2015-01-28
AU2017203246B2 (en) 2018-10-18
CN107789626A (en) 2018-03-13
JP2015510936A (en) 2015-04-13
HK1243921A1 (en) 2018-07-27
MX2019008817A (en) 2019-09-26
JP2015510928A (en) 2015-04-13
ZA201405862B (en) 2016-08-31
AU2013235518A1 (en) 2014-09-25
NZ628079A (en) 2016-05-27
NZ630471A (en) 2016-04-29
HK1204553A1 (en) 2015-11-27
NZ714288A (en) 2016-12-23
WO2013142274A1 (en) 2013-09-26
SG11201500409SA (en) 2015-03-30
NZ712594A (en) 2016-09-30
JP2018138602A (en) 2018-09-06
AU2013235518A2 (en) 2014-10-09
RU2599017C2 (en) 2016-10-10
RU2014142066A (en) 2016-05-10
CN104321056A (en) 2015-01-28
MY175764A (en) 2020-07-08
RU2669565C2 (en) 2018-10-12
CA2866755A1 (en) 2013-09-26
BR112014020113A8 (en) 2017-07-11
CN107157991A (en) 2017-09-15
BR112014020271A2 (en) 2017-06-20
EP2827851A4 (en) 2015-10-14
RU2016133305A (en) 2018-12-10
KR20140134284A (en) 2014-11-21
EP2827852A4 (en) 2016-03-02
BR112014020113A2 (en) 2017-06-20
NZ714662A (en) 2016-08-26
MX2014011129A (en) 2015-08-10
AU2013235507B2 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
NZ718163A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2014008284A (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof.
MX2014008283A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof.
UA115139C2 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
MY173215A (en) Acetylcysteine compositions and methods of use thereof
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
IN2014MN00333A (en)
MX2019003467A (en) Formulations and methods for vaginal delivery of antiprogestins.
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX2012005689A (en) Arachidonic acid analogs and methods for analgesic treatment using same.
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
GB201014391D0 (en) Drug composition and its use in therapy
IN2014MN02156A (en)
MX2016016039A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof.
GR1008228B (en) Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof
BR112013004714A2 (en) "combinations of hdac inhibitors with thrombocytopenia drugs and their uses"
IN2014DN10134A (en)
MX2015010594A (en) Lipobalanced long chain testosterone esters for oral delivery.
PH12015500070B1 (en) Pediatric oral liquid compositions containing nepadutant
CO6630144A2 (en) Association of xanthine oxidase and instatin inhibitors and their use
IN2013MU02111A (en)
IN2013MU02110A (en)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 MAR 2020 BY GRIFFITH HACK

Effective date: 20180108

LAPS Patent lapsed